FDA Clearance Tracker · K251978
LIAISON NES FLU A/B, RSV & COVID-19
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Dec 23, 2025
Substantially Equivalent
Time to decision
179 days
Received Jun 27, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K251978
- Device name
- LIAISON NES FLU A/B, RSV & COVID-19
- Applicant
- Diasorin Molecular, LLC
- Applicant location
- Cypress, CA
- Received
- Jun 27, 2025
- Decided
- Dec 23, 2025
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3981
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QOF. The earliest in FDA's data is DEN200031, decided Mar 17, 2021.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K251978
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Diasorin Molecular, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260333 · Decided Jun 15, 2026 · 133 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
K252387 · Decided Oct 30, 2025 · 91 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
- Simplexa C. auris Direct, Simplexa C. auris Positive Control Pack, Simplexa C. auris Sample Prep Kit (MOL3950, MOL3960, MOL5390)New device typeDe Novo
DEN230092 · Decided Jul 15, 2024 · 200 days after receipt
Device type: Device To Detect Microbial Colonization Directly From Clinical Specimens. (SBT) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.